Nanotechnology Approaches for Enhanced CNS Drug Delivery in the Management of Schizophrenia

Nanotechnology Approaches for Enhanced CNS Drug Delivery in the Management of Schizophrenia

Blog Article

Schizophrenia is a neuropsychiatric disorder mainly affecting the central nervous system (CNS),presented with auditory and visual hallucinations, delusion and withdrawal from society.Abnormal dopamine levels mainly characterise the disease; various theories of neurotransmittersexplain the pathophysiology of the disease.The current therapeutic approach deals with thesystemic administration of drugs other than the enteral route, altering the neurotransmitter levelswithin the brain and providing symptomatic relief.Fluid biomarkers help IMMUNO-MULTI in the early detectionof the disease, which would improve the therapeutic efficacy.However, the major challengefaced in CNS drug delivery is the blood-brain barrier (BBB).

Nanotherapeutic approaches mayovercome these limitations, which will improve safety, efficacy, and targeted drug delivery.Thisreview article addresses the main challenges faced in CNS drug delivery Melatonin GUMMIES Adults and the significance ofcurrent therapeutic strategies and nanotherapeutic approaches for a better understanding andenhanced drug delivery to the brain, which improve the quality of life of schizophrenia patients.